{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:04:35Z","timestamp":1787501075849,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia. Although serum clozapine levels can help guide treatment, they are underutilized owing to requirements for frequent venous blood draws and lack of immediate results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clozapine levels measured with a novel immunoassay technology (which enables point-of-care development) were compared with those measured by standard liquid chromatography\/tandem mass spectrometry (LC-MS\/MS). Frozen serum aliquots of 117 samples (N = 48 patients with schizophrenia on clozapine; N = 24 patients with schizophrenia not on clozapine; N = 45 healthy controls) were sent to a national reference laboratory (NRL) for clozapine level determination by LC-MS\/MS, and matching samples were subjected to novel immunoassay (3 runs). At a later date, another frozen aliquot from the same date was sent to the NRL for repeat testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The NRL obtained 18 false-positive clozapine results (mean 42.39 \u00b1 32.06, range 21\u2013159 ng\/mL) in participants not on clozapine (N = 3) and healthy controls (N = 15). The immunoassay showed no false-positive clozapine results. The clozapine levels were correlated between both assays (r = 0.84,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001), despite 16% higher clozapine levels with immunoassay (482.08 \u00b1 270.88 ng\/mL immunoassay, 414.98 \u00b1 186.29 ng\/mL LC-MS\/MS [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03]). Agreement analysis using concordance correlation coefficient (CCC) for LC-MS\/MS of the 2 aliquots yielded CCC = 0.869; 95% confidence interval = 0.690\u20130.970, whereas higher agreement results were observed for the 3 runs of immunoassay (CCC = 0.99; 95% confidence interval = 0.979\u20130.997).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The lack of false positives observed with immunoassay, higher repeat performance agreement, and good correlation with LC-MS\/MS may indicate the more robust performance of immunoassay than that of LC-MS\/MS clozapine-level determination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000777","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T01:01:47Z","timestamp":1595466107000},"page":"771-777","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of Novel Immunoassay With Liquid Chromatography\/Tandem Mass Spectrometry (LC-MS\/MS) for Therapeutic Drug Monitoring of Clozapine"],"prefix":"10.1097","volume":"42","author":[{"given":"Tiffany","family":"Buckley","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kitchen","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Maryland Psychiatric Research Center, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Vyas","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Maryland Psychiatric Research Center, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Siegfried","sequence":"additional","affiliation":[{"name":"Saladax Biomedical, Inc, Bethlehem, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshetu","family":"Tefera","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Maryland Psychiatric Research Center, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Maryland Psychiatric Research Center, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany A.","family":"DiPaula","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna L.","family":"Kelly","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Maryland Psychiatric Research Center, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.schres.2013.04.002","article-title":"Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature","volume":"147","author":"Lopez","year":"2013","journal-title":"Schizophr Res."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing barriers to clozapine underutilization: a national effort","volume":"69","author":"Kelly","year":"2018","journal-title":"Psychiat Serv."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","article-title":"Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study","volume":"21","author":"Gaertner","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistantschizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatry."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/schbul\/sbp130","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr Bull."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ps.52.6.805","article-title":"Using drug claims data to assess the relationship of medication adherence with hospitalization and costs","volume":"52","author":"Svarstad","year":"2001","journal-title":"Psychiat Serv."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00005650-200208000-00002","article-title":"Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission","volume":"40","author":"Valenstein","year":"2002","journal-title":"Med Care."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am J Psychiatry."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatry Res."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","article-title":"Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review","volume":"152","author":"Zipursky","year":"2014","journal-title":"Schizophr Res."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/NDT.S163839","article-title":"Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations","volume":"14","author":"Mayerova","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: a systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophr Res."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0004867412438871","article-title":"A review of the use of clozapine levels to guide treatment and determine cause of death","volume":"46","author":"Stark","year":"2012","journal-title":"Aust N Z J Psychiat."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0000000000000478","article-title":"Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved?","volume":"36","author":"Bogers","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3371\/CSRP.KEBE.070415","article-title":"Blood draw barriers for treatment with clozapine and development of a point-of-care monitoring device","volume":"12","author":"Kelly","year":"2018","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2147\/NDT.S216803","article-title":"Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes","volume":"15","author":"Kalaria","year":"2019","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/acps.12193","article-title":"Practitioner attitudes to clozapine initiation","volume":"130","author":"Gee","year":"2014","journal-title":"Acta Psychiatr Scand."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2045125314566808","article-title":"Clozapine prescribing in the UK: views and experience of consultant psychiatrists","volume":"5","author":"Tungaraza","year":"2015","journal-title":"Ther Adv Psychopharm."},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BjPsych Bull."},{"key":"R33-20230928","first-page":"66","article-title":"Assessment of capacity to give consent to research participation: state-of-the-art and beyond","volume":"1","author":"DeRenzo","year":"1998","journal-title":"J Health Care Law Policy."},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.forsciint.2013.03.021","article-title":"Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Sci Int."},{"key":"R36-20230928","article-title":"Evaluation of precision performance of quantitative measurement methods; approved guideline\u2014second edition","volume":"24","author":"Tholen","year":"2004","journal-title":"Evaluation."},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/10543400701376480","article-title":"An overview on assessing agreement with continuous measurements","volume":"17","author":"Barnhart","year":"2007","journal-title":"J Biopharm Stat."},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1601-5215.2012.00637.x","article-title":"A false positive for clozapine using high-pressure liquid chromatography with ultraviolet detection","volume":"24","author":"Lertxundi","year":"2012","journal-title":"Acta Neuropsychiatr."},{"key":"R40-20230928","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FTD.0b013e3182666c62","article-title":"A puzzling case of increased serum clozapine levels in a patient with inflammation and infection","volume":"34","author":"Espnes","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R41-20230928","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R42-20230928","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2020.1698545","article-title":"The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy","volume":"19","author":"Costa-Dookhan","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"R43-20230928","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.jcp.0000116646.91923.2f","article-title":"Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene","volume":"24","author":"Eap","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"R44-20230928","first-page":"155","article-title":"Existing and emerging technologies for point-of-care testing","volume":"35","author":"St John","year":"2014","journal-title":"Clin Biochem Rev."},{"key":"R45-20230928","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00007691-200308000-00009","article-title":"Monitoring clozapine: are fingerprick blood and plasma clozapine levels equivalent to arm venipuncture blood and plasma levels?","volume":"25","author":"Goossen","year":"2003","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T21:06:09Z","timestamp":1695848769000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000777","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,17]]}}}